exatecan

Exatecan (DX-8951f) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM (0.975 μg mL).Exatecan has antitumor activity and may be used in cancer research.

Exatecan Mesylate (DX8951f) is a DNA topoisomerase I inhibitor (IC50: 2.2 μM, 0.975 μg mL).

(4-NH2)-Exatecan is a topoisomerase inhibitor with potential anticancer activity for the synthesis of antibody drug conjugates (ADCs).

Exatecan (GMP) refers to the GMP grade reagents of Exatecan. Exatecan (DX-8951f) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM (0.975 μg mL).Exatecan has antitumor activity and may be used in cancer research.

DBCO-PEG3-VC-Exatecan (compound 25) is a Drug-Linker Conjugate for ADC (ADC Drug-Linker Conjugate), consisting of the ADC linker (DBCO-PEG3-VC) coupled with the DNA topoisomerase I (topoisomeraseI) inhibitor Exatecan. This conjugate is utilized in the development of antibody-drug conjugates for targeted cancer therapy.

Compound 94 (MC-GGFG-PAB-Exatecan) is an ADC drug-linker conjugate utilized in the synthesis of antibody-drug conjugates (ADCs).

Val-Ala-PABC-N(Mesylpropane)-Exatecan is a drug-linker conjugate (Drug-Linker Conjugates for ADC) composed of a cleavable Val-Ala-PABC-N(Mesylpropane) linker and Exatecan, a topoisomerase I inhibitor.

GGFG-PAB-Exatecan TFA consists of the toxin molecule Exatecan and the linker GGFG-PAB, and it serves as a drug-linker conjugate for synthesizing ADC molecules.

2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan is a drug-linker conjugate used in ADC (antibody-drug conjugate) applications. It consists of a linker and Exatecan.

Mal-Exatecan, a derivative of Exatecan modified with maleimide (Mal), functions as an inhibitor of DNA topoisomerase I (topoisomeraseI).

Exatecan hydrochloride (DX-8951f hydrochloride) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM (0.975 μg mL).Exatecan hydrochloride has antitumor activity and may be used in cancer research.

C-lock-GGFG-Exatecan is a thiol-reactive drug linker. GGFG is a peptidase-activatable peptide. After entering the lesion, it can enable the release and activation of the payload Exatecan. C-lock-GGFG-Exatecan is commonly used in the synthesis of antibody-drug conjugates (ADCs).

MC-VC-PAB-Exatecan is a part of the antibody-conjugated active molecule ADC. It is formed by coupling the cleavable ADC linker (MC-VC-PAB) with the payload Exatecan. MC-VC-PAB-Exatecan is commonly used in the synthesis of ADC compounds.

Exatecan-amide-cyclopropanol is an anticancer agent that inhibits the proliferation of SK-BR-3 cells (IC50: 0.12 nM) and U87 cells (IC50: 0.23 nM).

Exatecan Intermediate 1 is a useful organic compound for research related to life sciences. The catalog number is T67020 and the CAS number is 110351-94-5.

MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is an agent-linker conjugate for antibody-drug conjugates (ADCs), incorporating Exatecan, a DNA Topoisomerase I inhibitor (IC 50 = 2.2 μM) [1].

MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan is a agent-linker conjugates for ADC , consisting Exatecan . Exatecan is a DNA Topoisomerase I inhibitor (IC 50 =2.2 μM) [1] .

Gly-Cyclopropane-Exatecan, a DNA Topoisomerase I inhibitor containing Exatecan, is key in synthesizing the anti-B7-H4 ADC, specifically the ADC hu2F7-Exatecan (compound 34). This compound demonstrated antitumor activity both in vivo and in vitro [1].

Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan is a conjugated compound used in the synthesis of antibody-drug conjugates (ADCs), featuring a topoisomerase inhibitor derivative linked via a linker to a specific ligand unit[1].

MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a conjugate of the DNA topoisomerase I inhibitor DX-8951 and a cathepsin-cleavable antibody-drug conjugate (ADC) linker, designed for targeted cancer therapy applications.

Val-Ala-PABC-Exatecan is a Drug-Linker Conjugate for Antibody-Drug Conjugate (ADC) synthesis, comprising a cleavable Tesirine linker (Val-Ala-PABC) and the topoisomerase I inhibitor Exatecan. It is used in the construction of ADC molecules, including Mal-PEGn-amide-va-Exatecan [1].

MC-VA-PAB-Exatecan is an agent-linker conjugate designed for Antibody-Drug Conjugate (ADC) applications, comprising the ADC linker (peptide MC-VA-PAB) and the DNA topoisomerase I inhibitor Exatecan. Synthesis of this conjugate has demonstrated promising antitumor activity [1].

Mal-PEG8-Val-Ala-PAB-Exatecan (Compound 9b), an antibody-drug conjugate linker (ADC linker), binds Nectin-4 polypeptides to chemotherapeutic agents for use in cancer research [1].

MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan is an agent-linker conjugate designed for antibody-drug conjugate (ADC) applications, comprised of an ADC linker (MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic acid) and the DNA topoisomerase I inhibitor, Exatecan. This conjugate is utilized in cancer research [1].